The conference on Coronavirus & Research brings together top basic, translational, and clinical researchers from around the world to share the latest studies, risk factors, important developments, and best research methods in the ongoing battle against Covid – 19 and related infectious diseases. Corona 2021 will be held at Milan, Italy on March 29 – 30, 2021.
Various topics will be presented and discussed in which topics are limited to Basic and translational science, Clinical science, Epidemiology, Public health, Prevention, risk factors, case reports and social sciences.
The conference aims to
Why to attend?
Pneumonia of unknown cause detected in Wuhan, China on 31 December 2019 with was confirmed by WHO as Covid19 (Novel Coronavirus Disease 2019). The outbreak was declared a Public Health Emergency of International Concern. Many experts and funders addressed the issues for developing easy-to-apply diagnostics, accelerating existing vaccine candidates and preventing infection. Several therapeutics and vaccines were in clinical trials and people were informed to protect themselves to control the spread. With the experts and healthcare professions; this is the best opportunity to reach the largest assemblage of participants from the coronavirus research. This event will provide an opportunity to build and expand your network with various people, discuss novel strategies and gives chance to make collaboration with other universities and research labs. Conduct presentations, awareness, drug discovery, clinical trials, distribute information, meet with current and potential scientists and receive name recognition at this 2-day event.
Who should attend?
Target audience for Coronavirus 2021 Podcast Includes
The Coronavirus Webcast welcomes all the eminent Professors of virology and infectious diseases to share their research work and experiences; we are open for all the scientists from all over the globe with their new findings. We encourage young researchers, students to participate and share their ideas in the conference. We are also honor to welcome Directors, Vice Presidents, Head of technology from industries, R&D Chemist, virologists, healthcare providers, Life Sciences Specialist, and Exhibitors are also welcoming to exhibit their projects, products and findings.
Members Associated with Emerging Infectious Diseases Research
The mission of the Coronavirus 2021 conference in Health Care initiative was to assist in reducing dissemination of infections associated with healthcare, by assisting with the assessment, planning, implementation and evaluation of national infection control policies. The ultimate goal is to endorse quality promotion of health care which is safe for patients, health care workers, others in the health care setting and the environment, in the Infectious Diseases field
Hospitals Associated with Emerging Infectious Diseases Research
Healthcare-associated infections (HAI) are a threat to patient safety. CDC provides national leadership in surveillance, outbreak investigations, laboratory research, and prevention of healthcare-associated infections. CDC uses knowledge gained through these activities to detect infections and develop new strategies to prevent healthcare-associated infections. Public health action by CDC and other healthcare partners has led to improvements in clinical practice, medical procedures, and the ongoing development of evidence-based infection control guidance and prevention successes.
Major Infectious Diseases Research Associations around the Globe
Market Research on Emerging Diseases
The global infectious disease market size was valued at USD 46.88 billion in 2017 and is projected to grow at a CAGR of 6.6% during the forecast period. Rising prevalence of infectious ailments, increasing expenditure to boost the penetration rate of treatments of these diseases, rising initiatives for creating awareness about treatments & diagnosis of these conditions, and increasing clinical trial studies for development of new drugs are likely to be the factors responsible for growth of this market. In 2016, the HIV segment held the largest share i.e., 45.9% of the market. Increasing prevalence of HIV, rising funding activities for patients suffering from HIV, increasing supply of free HIV self-test kits in African countries, and rising awareness campaigns are the key factors responsible for the largest share held by this segment. In addition, WHO aims to test 90% and treat 80% of the people suffering from HBV and HCV by 2025, through its Global Health Sector Strategy on viral hepatitis, which is further expected to contribute to the growth in this segment. 
Market Analysis & Report – Covid – 19
The market for drugs and vaccines to combat infectious diseases is expanding overall, but with wide variation in sales among its segments. This article analyzes the products, trends and dealmaking underlying these changes. 
Figure 1: The antiviral market has doubled in size—from $20 billion in 2010 to $42 billion in 2017 and then gradually decreases to $39 billion.
Overview — assessing the impact of the COVID-19 pandemic on drug markets
In the context of the recent global events linked to the COVID-19 pandemic, the EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) recognised an urgent need to understand the impact of these developments on drug markets in order to anticipate emerging threats and meet immediate and longer-term data needs for policy-making and operational responses.
As well as improving responses to the current crisis this will also help strengthen our capacity to understand, foresee and forewarn how drug markets react to rapid global changes. Overall, the EMCDDA’s objective is to strengthen EU-level preparedness and response to drug market changes. This must be done rapidly and at a time when many of our conventional data collection sources are facing operational difficulties. 
The effect of COVID-19 on drug markets in the EU
The effect COVID-19 is having on the EU's largest criminal marke is explored in EU Drug Markets: Impact of COVID-19, produced jointly with Europol. The analysis reports higher prices, local shortages and reduced purity for some drugs, while noting continued violence among suppliers and distributors. It also shows how organised crime groups remain active and resilient, by ‘adapting transportation models, trafficking routes and concealment methods’, even during the pandemic.
The EMCDDA and Europol are working together to improve our understanding of drug market developments under COVID-19 and their impact on internal security and public health in the EU. The findings are based on opinions collected through a targeted EMCDDA online survey of drug experts in the EU Member States, Europol’s operational intelligence gathering on organised crime and structured monitoring of open source information. 
Coronavirus | Corona | Emerging coronavirus | Covid 2019 | Covid19 | Coronavirus Disease | Novel Coronavirus | COVID-19 | Middle East Respiratory Syndrome | MERS-CoV | Acute Respiratory Syndrome | SARS-CoV | zoonotic | Respiratory symptoms | Pneumonia | Kidney Failure | Coughing | Sneezing | New Virus | High Blood Pressure | Heart Problems | Diabetes | Transmission | Virology | Viral testing | RNA testing protocols | Imaging | Radiographs | Computed tomography | Fatigue | Myalgia | Anorexia | Sputum Production | Sore Throat | Personal Hygiene | Hand Washing | Surgical Mask | Social distancing | Respiratory Hygiene | Self-isolation | Respiratory Tract Infections | Coronavirus Disease 2019
Coronavirus Conferences | Coronavirus news | Covid Conferences | Wuhan | Corona pandemic | coronavirus update | cdc coronavirus | Coronavirus wiki | Coronavirus treatment | Coronavirus Italy | Corona treatment | Coronavirus congress | Coronavirus Events | Corona meetings | Covid Meetings | Covid updates | Virology Conferences | Virology Congress | Virus Meet | Virology Meetings | Infections Disease Conference | Infections Congress | Infectious Disease Meet | Emerging infectious Diseases Conference| Emerging Infection Diseases Congress